S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
Free Trial

Compare Stocks

→ Start loving Mondays like this (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
C$19.02
+0.1%		C$17.34
C$14.58
▼
C$19.41
C$931.98MN/A26,163 shs26,557 shs
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
▼
$73.02
$4.62B0.452.07 million shs74 shs
A Guide To High-Short-Interest Stocks Cover
A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
+0.32%+0.16%+10.34%+16.92%+17.94%
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/AN/AN/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/AN/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/AN/A0.00∞N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/AN/AN/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/AN/AN/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17

Ownership

Institutional Ownership

CompanyInstitutional Ownership
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/A
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Gold Bullion ETF (CAD-Hedged) stock logo
CGL
iShares Gold Bullion ETF (CAD-Hedged)
N/A49.00 millionN/ANot Optionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable

GBT, CGL, and GFT Headlines

SourceHeadline
Executive ProfilesExecutive Profiles
pharmexec.com - April 17 at 12:57 AM
What the Amex GBT-CWT merger means for the travel industryWhat the Amex GBT-CWT merger means for the travel industry
travelweekly-asia.com - March 26 at 7:18 AM
Amex GBT set to acquire CWT for USD 570mnAmex GBT set to acquire CWT for USD 570mn
travelbizmonitor.com - March 26 at 2:18 AM
Amex GBT to purchase CWT for $871mAmex GBT to purchase CWT for $871m
travelweekly.com.au - March 26 at 2:18 AM
Amex GBT to acquire rival CWT in $570m dealAmex GBT to acquire rival CWT in $570m deal
c-mw.net - March 25 at 4:18 PM
Amex GBT acquires its competitor CWTAmex GBT acquires its competitor CWT
fvw.de - March 25 at 9:25 AM
Amex GBT buys rival CWT in $570m dealAmex GBT buys rival CWT in $570m deal
businesstravelnewseurope.com - March 25 at 9:25 AM
Amex GBT to Acquire CWT for $570 MillionAmex GBT to Acquire CWT for $570 Million
skift.com - March 25 at 9:25 AM
How Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4BHow Dr. Ted Love, a cardiologist turned biotech executive, sold his sickle cell company to Pfizer for $5.4B
msn.com - March 22 at 4:27 PM
GBT Warns Community of Fraudulent Message CirculationGBT Warns Community of Fraudulent Message Circulation
bossierpress.com - March 18 at 9:38 PM
Global TV Trivia at Blood BrothersGlobal TV Trivia at Blood Brothers
blogto.com - March 7 at 10:00 AM
GBT set to reintroduce National LotteryGBT set to reintroduce National Lottery
dailynews.co.tz - March 7 at 10:00 AM
Volume three of 100 GBT Clinical Cases unveiledVolume three of 100 GBT Clinical Cases unveiled
dentistry.co.uk - February 16 at 9:56 AM
Global Cystic Fibrosis Therapeutics Market Expected to Reach US$ 24.35 Billion by 2028 with a CAGR of 14.40% from 2022Global Cystic Fibrosis Therapeutics Market Expected to Reach US$ 24.35 Billion by 2028 with a CAGR of 14.40% from 2022
medgadget.com - February 15 at 10:37 AM
How Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 BillionHow Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion
forbes.com - February 5 at 3:22 PM
Amex GBT addresses fraud with Expedia Group’s fraud prevention solutionAmex GBT addresses fraud with Expedia Group’s fraud prevention solution
travelweek.ca - February 1 at 1:47 PM
Global Wearable Blood Pressure Monitor Industry Set to Reach US$ 8 Billion by 2032, Fueled by Impressive 15%-16% CAGR | Insights by FMI AnalysisGlobal Wearable Blood Pressure Monitor Industry Set to Reach US$ 8 Billion by 2032, Fueled by Impressive 15%-16% CAGR | Insights by FMI Analysis
fmiblog.com - January 30 at 7:32 PM
Answering the call for excellence with GBTAnswering the call for excellence with GBT
dentistry.co.uk - January 23 at 6:19 AM
Global Brain Tumor Drugs Industry is expected to reach a significant US$ 6.30 Billion by 2033, according to FMI’s forecastGlobal Brain Tumor Drugs Industry is expected to reach a significant US$ 6.30 Billion by 2033, according to FMI’s forecast
fmiblog.com - January 22 at 7:20 AM
GBT Realty to Develop 42,000 SF Shopping Center in Kyle, TexasGBT Realty to Develop 42,000 SF Shopping Center in Kyle, Texas
rebusinessonline.com - January 17 at 4:14 PM
Better Therapeutics, Glooko partner on digital diabetes managementBetter Therapeutics, Glooko partner on digital diabetes management
massdevice.com - January 4 at 6:08 PM
US biotech firm addresses critical gap in blood pressure managementUS biotech firm addresses critical gap in blood pressure management
msn.com - December 27 at 8:55 PM
Should we pay people for donating blood?Should we pay people for donating blood?
bbc.com - December 20 at 1:36 PM
Get on board with GBT for 2024Get on board with GBT for 2024
dentistry.co.uk - December 20 at 8:35 AM

New MarketBeat Followers Over Time

Top Headlines

All Headlines

Company Descriptions

iShares Gold Bullion ETF (CAD-Hedged) logo

iShares Gold Bullion ETF (CAD-Hedged)

TSE:CGL
Global Blood Therapeutics logo

Global Blood Therapeutics

NASDAQ:GBT
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.